Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Nebulized CSL787 in Healthy and NCFB Subjects
NCT04643587Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Dec 2020
- Primary completion
- Mar 2023
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of CSL787 in Non-Cystic Fibrosis Bronchiectasis (NCFB) (8 arms), sponsored by CSL Limited. Primary endpoints: Number of subjects with treatment emergent adverse events at 21 days and Percent of subjects with treatment emergent adverse events at 21 days. Started Dec 2020; status: completed.
02
Drugs
CSL787
03
Conditions
Non-Cystic Fibrosis Bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT04643587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04643587.